Expression of metastasis suppressor 1 is associated with clinical data and overall survival of breast cancer patients
Keywords:
MTSS1 gene expression, ฺBreast Cancer, Overall survivalAbstract
Metastasis suppressor 1 or MTSS1 is a protein that plays an important role in cancer suppressor to metastasis. It is not currently known how MTSS1 controls cancer cells. Therefore, this study aimed to determine the association of MTSS1 gene expression with sex, age, pathological characteristics, cancer stage, metastasis, and overall survival. The expression of the MTSS1 gene was studied in 118 female fresh tissue samples with breast cancer aged 34-82 years (mean 53.2+9.8 years). Pathological characteristics of fresh tissue samples were; invasive ductal carcinoma as 105 samples (88.98%) of all fresh tissue samples by TaqMan real-time PCR technique. Survival of patients was monitored from medical records, and civil registry. An analysis of the association with various variables showed that MTSS1 gene expression increased from 0.003-19.284 times compared with beta-actin (internal control) gene. In 84 samples, MTSS1 expression increased as 1.83±2.89 fold, and fresh tissue samples from patients with stage 3 and 4 cancer showed a 1.98±3.65 times increase in MTSS1 gene expression. The expression of the MTSS1 gene was slightly greater in patients with advanced cancer (stage 3 and 4) than in the first stage (stage 1 and 2), but there was no statistically significant difference (P=0.899).Cancer metastasis as 19 samples (16.10%) increased MTSS1 expression than the group without metastasis. However, there was no statistically significant difference (P=0.413). The MTSS1 gene expression was found in patients with less than or equal to 60-month survival rate and more than 60-month survival rate. There was a statistically significant difference (P=0.048), so it was concluded that MTSS1 expression was not associated with age pathological characteristics and cancer metastasis, but correlated with overall survival.This result may be used to predict further or prognosis the survival rate of breast cancer.
References
Ataollahi, M. R, Sharifi J, Paknahad M. R, Paknahad A .Breast cancer and associated fac-tors: a review. J Med Life 2015;8:6-1.PMID: 28316699.
Parr C, Jiang G. W. Metastasis suppressor 1 (MTSS1) demonstrates prognostic value and anti-metastatic properties in breast cancer. Eur J Cancer 2009; 45:1673-83.PMID:19 328678.
Du P, Ye L, Ruge F, Yang Y, Jiang W.G. Metastasis suppressor-1, MTSS1, acts as a putative tumour suppressor in human bladder cancer. Anticancer Res 2011; 31:3205-12.PMID: 21965727.
Fournier R. E, Ruddle F. H. Stable association of the human transgenome and host murine chromosomes demonstrated with trispecific microcell hybrid. Proc Natl Acad Sci U S A1977;74: 3937-41.doi:10.1073/pnas.74.9.3937.
Fournier R. E, Ruddle, F. H. Microcell-mediated transfer of murine chromosomes into mouse, Chinese hamster, and human somatic cells.PNAS 1977;74:319-23.doi.org/10.1073/pnas.74.1.319.
Yan J, Yang Q, Huang Q. Metastasis suppressor genes. Histol Histopathol 2013;28:285-92.PMID: 23348381.
Freije JM, MacDonald NJ, Steeg PS. Nm 23 and tumour metastasis: basic and translational advances. Biochem Soc Symp 1998;63:261-71.PMID: 9513729.
Gunduz M, Ayhan A, Gullu I, Onerci M, Hosal AS, Gursel B, et al. Nm23 Protein expression in larynx cancer and the relationship with metastasis. Eur J Cancer 1997;33:2338-41.PMID: 9616278.
Lee YG, Macoska JA, Korenchuk S, Pienta KJ. MIM, a potential metastasis Suppressor gene in bladder cancer. Neoplasia 2002;4:291-4.PMID:12082544.
Wang F, Liu Y, Zhang H. Loss of MTSS1 expression is an independent prognostic factor for Hilar cholangiocarcinoma. Pathol Oncol Res 2013;19:815-20.PMID: 23852458.
Mattila P. K, Salminen M, Yamashiro T, Lappalainen P. Mouse MIM, a tissue-specific regulator of cytoskeletal dynamics, interacts with ATP-actin mono-mers through its C-terminal WH2 domain. J Biol Chem 2002;
:82452-59.PMID: 12482861
Lee SH, Kerff F, Chereau D, Ferron F, Klug A , Dominguez R. Structural basis for the actin-binding function of missing-in-metastasis.Structure 2007;15:145-55. PMID:17292833.
Mattila, P. K, Pykäläinen A, Saarikangas J, Paavilainen V. O, Vihinen H, Jokitalo E, et al. Missing-in-metastasis and IRSp53 deform PI(4,5)P2-rich membranes by an inverse BAR domain-like mechanism. J Cell Biol 2007;
:953-64. PMID:17371834.
Glassmann A, Molly S, Surchev L, Nazwar T.A, Holst M, Hartmann W,et al. Developmentalexpression and differentiation-related neuron-specific splicing of metastasis suppressor 1 (Mtss1) in normal and transformed cerebellar cells. BMC Dev Biol 2007;7:111.doi:10.1186/1471-213X-7-111.
Woodings JA, Sharp SJ, Machesky LM. MIM-B, a putative metastasis suppressor protein, binds to actin and to protein tyrosine phosphatase delta. Biochem J 2003;371:463-71.PMID:12570871.
Kayser G, Csanadi A, Kakanou S, Prasse A, Kassem A, Stickeler E, et al. Down regulation of MTSS1 expression is an independent prognosticator in squamous cell carcinoma of the lung. Br J Cancer 2015;112:866-73.
doi:10.1038/bjc.2015.2.
Callahan C. A, Ofstad T, Horng L, Wang J. K, Zhen H. H, Coulombe P. A, et al . MIM/BEG4, a sonic hedgehog-responsive gene that potentiates Gli-dependent transcripttion.Genes Dev 2004;18, 2724-29. doi: 10.1101/gad.1221804.
Cachin F, Prince H. M, Hogg A, Ware R. E, Hicks R. J. Powerful prognostic stratifi-cation by [18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy. J Clin Oncol 2006;24:3026-31. doi:10.1200/JCO.2005.04.6326.
Ma S, Guan XY, Lee Tk, Chan KW. Clinicopathological significance of missing in metastasis B expression in hepatocellular carcinoma. Hum Pathol 2007;38:1201-6.
Parr C, Jiang WG. Metastasis suppressor 1 (MTSS1) demonstrates prognostic value and anti-metastatic properties in breast cancer. Eur J Cancer 2009;45:1673-83.
Loberg R. D, Neeley C. K, Adam-Day L. L, Fridman Y, St John L. N, Nixdorf S , et al. Differential expression analysis of MIM (MTSS1) splice variants and a functional role of MIM in prostate cancer cell Int J Oncol 2005;26:1699-705.
Dawson J. C, Timpson P, Kalna G, Machesky L. M. Mtss1 regulates epidermal growth factor signaling in head and neck squamous carcinoma cells.Oncogene 2012; 31:1781-93. doi:10.1038/onc.2011.376.
Liu K, Wang G, Ding H, Chen Y, Yu G , Wang J. Downregulation of metastasis suppressor 1(MTSS1) is associated with nodal metastasis and poor outcome in Chinese patients with gastric cancer. BMC cancer 2010;10:428.
Xie F, Ye L, Chen J, Wu N, Zhang Z, Yang Y, et al. The impact of Metastasis Suppressor-1, MTSS1, on oesophageal squamous cell carcinoma and its clinical signifi-cance. J Transl Med 2011;9:1-10.
Cong Z, Zhao Q, Yang B, Cong D, Zhou Y, Lei X, et al. Ginsenoside Rh3 Inhibits Proliferation and Induces Apoptosis of Colorectal Cancer Cells. Pharmacology2020;105:329-38.
Sung H, Ferlay J, Siegel R. L, Laversanne M, Soerjomataram I, Jemal A,et al. Global cancer statistics 2020: GLOBOCAN estimatesof incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-49
Zhong J, Shaik S, Wan L, Tron A. E, Wang Z, Sun L, et al. SCF β-TRCP targets MTSS1 for ubiquitination-mediated destructtion to regulate cancer cell proliferation and migration.Oncotarget 2013;4:2339-53.
Nixdorf S, Grimm M. O, Loberg R., Marreiros A, Russell P. J, Pienta K, et al. Expression and regulation of MIM (Missing In Metastasis), a novel putative metastasis suppressor gene, and MIM-B, in bladder cancer cell lines. Cancer Lett 2004;215:209-20.
Du P, Ye L, Li H, Yang Y, Jiang W. G. The tumour suppressive role of metastasis suppressor-1, MTSS1, in human kidney cancer, a possible connection with the SHH pathway. J Exp Ther Oncol 2012;10:91-9.PMID: 23350348.
Folgueira M. A, Carraro D. M, Brentani H, Patrão D. F, Barbosa E. M, Netto M. M, et al. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 2005;11:7434-43.
Downloads
Published
Issue
Section
License
บทความทีตีพิมพ์ในวารสารโรคมะเร็งนี้ถือว่าเป็นลิขสิทธิ์ของมูลนิธิสถาบันมะเร็งแห่งชาติ และผลงานวิชาการหรือวิจัยของคณะผู้เขียน ไม่ใช่ความคิดเห็นของบรรณาธิการหรือผู้จัดทํา
